ThinkEquity upgrades ANDS to Buy from Accumulate and raises their tgt to $4.ANDS announced the final data sets from the proof-of-concept study with ANA-773. The data demonstrates that the oral immunomodulator ANA-773 is active and effective as an all-oral HCV regimen.
No comments:
Post a Comment